BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37874744)

  • 1.
    Contreras Yametti GP; Robbins G; Chowdhury A; Narang S; Ostrow TH; Kilberg H; Greenberg J; Kramer L; Raetz E; Tsirigos A; Evensen NA; Carroll WL
    Leuk Lymphoma; 2024 Jan; 65(1):78-90. PubMed ID: 37874744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
    Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
    Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
    Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
    Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
    Dong Y; Zhao X; Feng X; Zhou Y; Yan X; Zhang Y; Bu J; Zhan D; Hayashi Y; Zhang Y; Xu Z; Huang R; Wang J; Zhao T; Xiao Z; Ju Z; Andreassen PR; Wang QF; Chen W; Huang G
    Leukemia; 2019 Nov; 33(11):2585-2598. PubMed ID: 30967619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Mar BG; Chu SH; Kahn JD; Krivtsov AV; Koche R; Castellano CA; Kotlier JL; Zon RL; McConkey ME; Chabon J; Chappell R; Grauman PV; Hsieh JJ; Armstrong SA; Ebert BL
    Blood; 2017 Dec; 130(24):2631-2641. PubMed ID: 29018079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
    Oshima K; Khiabanian H; da Silva-Almeida AC; Tzoneva G; Abate F; Ambesi-Impiombato A; Sanchez-Martin M; Carpenter Z; Penson A; Perez-Garcia A; Eckert C; Nicolas C; Balbin M; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Devidas M; Loh ML; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando AA
    Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11306-11311. PubMed ID: 27655895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.
    Waanders E; Gu Z; Dobson SM; Antić Ž; Crawford JC; Ma X; Edmonson MN; Payne-Turner D; van de Vorst M; Jongmans MCJ; McGuire I; Zhou X; Wang J; Shi L; Pounds S; Pei D; Cheng C; Song G; Fan Y; Shao Y; Rusch M; McCastlain K; Yu J; van Boxtel R; Blokzijl F; Iacobucci I; Roberts KG; Wen J; Wu G; Ma J; Easton J; Neale G; Olsen SR; Nichols KE; Pui CH; Zhang J; Evans WE; Relling MV; Yang JJ; Thomas PG; Dick JE; Kuiper RP; Mullighan CG
    Blood Cancer Discov; 2020 Jul; 1(1):96-111. PubMed ID: 32793890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.
    Skucha A; Ebner J; Grebien F
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
    Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
    Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-Mediated Induction of Relapse-Specific
    Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
    Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of functional cooperative mutations of SETD2 in human acute leukemia.
    Zhu X; He F; Zeng H; Ling S; Chen A; Wang Y; Yan X; Wei W; Pang Y; Cheng H; Hua C; Zhang Y; Yang X; Lu X; Cao L; Hao L; Dong L; Zou W; Wu J; Li X; Zheng S; Yan J; Zhou J; Zhang L; Mi S; Wang X; Zhang L; Zou Y; Chen Y; Geng Z; Wang J; Zhou J; Liu X; Wang J; Yuan W; Huang G; Cheng T; Wang QF
    Nat Genet; 2014 Mar; 46(3):287-93. PubMed ID: 24509477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
    Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C
    Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
    Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
    Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
    Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
    Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance.
    Saint Fleur-Lominy S; Evensen NA; Bhatla T; Sethia G; Narang S; Choi JH; Ma X; Yang JJ; Kelly S; Raetz E; Harvey RC; Willman C; Loh ML; Hunger SP; Brown PA; Getz KM; Meydan C; Mason CE; Tsirigos A; Carroll WL
    Cancer Res; 2020 Dec; 80(23):5189-5202. PubMed ID: 33067268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
    Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
    Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic abnormalities associated with the relapse of childhood leukemia].
    Yoshida K
    Rinsho Ketsueki; 2016 Jul; 57(7):919-24. PubMed ID: 27498739
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.